Immunocore Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Immunocore Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013988
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Immunocore Ltd (Immunocore) is a biotechnology company that focuses on the development of immunotherapeutic drugs for the treatment of cancer, infectious diseases and autoimmune diseases. The company develops its drugs using its proprietary T cell receptor (TCR) technology. Its products under development include IMCgp100, an ImmTAC reagent used to treat patients with advanced cutaneous and uveal melanomas. The company has collaboration with various pharmaceutical companies, to develop its product candidates for the treatment of metastatic cutaneous melanoma; cancer; and other indications. Immunocore is headquartered in Abingdon, the UK.

Immunocore Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Immunocore Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Immunocore Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Immunocore Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Immunocore Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Immunocore Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Immunocore Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
CMC Biologics Enters into Agreement with Immunocore 10
Eli Lilly Enters into Co-Discover and Development Agreement with Immunocore 11
Licensing Agreements 12
MedImmune And Immunocore Enter Into Licensing Agreement To Develop Cancer Therapies 12
Immunocore Enters Into Licensing Agreement With GSK For ImmTACs 14
Immunocore Enters Into Licensing And Research Agreement With Genentech For Cancer Drugs 15
Equity Offering 16
Immunocore Raises USD320 Million in Financing Round 16
Acquisition 17
Medigene Sells Minority Stake in Immunocore 17
Immunocore Ltd – Key Competitors 18
Immunocore Ltd – Key Employees 19
Immunocore Ltd – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Strategy And Business Planning 21
Jul 07, 2017: Immunocore and MEPC announce significant laboratory expansion at Milton Park in Oxfordshire, UK 21
Corporate Communications 22
Oct 04, 2017: Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer 22
May 12, 2017: Abbas Hussain Joins the Board of Immunocore as Non-Executive Director 23
May 12, 2017: Immunocore: Abbas Hussain Joins the Board of Immunocore as Non-executive Director 24
Oct 12, 2016: Immunocore Appoints Paul Fry as Chief Financial Officer 25
Product News 26
07/13/2016: UK treatment targets HIV’s last hiding place 26
Jun 08, 2016: Immunocore’s ImmTAV shown to redirect the immune system to kill HIV-infected cells from patients treated with antiretroviral therapy 27
05/08/2017: Immunocore identifies second novel ImmTAC in the GSK collaboration 28
Product Approvals 29
Jan 25, 2016: Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma 29
Clinical Trials 30
Jun 06, 2016: Immunocore Presents Positive IMCgp100 Phase I Data at the 2016 ASCO Annual Meeting 30
Mar 30, 2016: Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Immunocore Ltd, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Immunocore Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Immunocore Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Immunocore Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Immunocore Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Immunocore Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
CMC Biologics Enters into Agreement with Immunocore 10
Eli Lilly Enters into Co-Discover and Development Agreement with Immunocore 11
MedImmune And Immunocore Enter Into Licensing Agreement To Develop Cancer Therapies 12
Immunocore Enters Into Licensing Agreement With GSK For ImmTACs 14
Immunocore Enters Into Licensing And Research Agreement With Genentech For Cancer Drugs 15
Immunocore Raises USD320 Million in Financing Round 16
Medigene Sells Minority Stake in Immunocore 17
Immunocore Ltd, Key Competitors 18
Immunocore Ltd, Key Employees 19
Immunocore Ltd, Subsidiaries 20

★海外企業調査レポート[Immunocore Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Schindler Holding Ltd.:戦略・SWOT・企業財務分析
    Schindler Holding Ltd. - Strategy, SWOT and Corporate Finance Report Summary Schindler Holding Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Seres Therapeutics Inc (MCRB):製薬・医療:M&Aディール及び事業提携情報
    Summary Seres Therapeutics Inc (Seres), is a microbiome therapeutics platform company that develops a novel class of biological drugs. The company creates a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. The company’ …
  • Tan Chong Motor Holdings Berhad (TCHONG):企業の財務・戦略的SWOT分析
    Tan Chong Motor Holdings Berhad (TCHONG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • The Independent Order of Foresters:企業の戦略的SWOT分析
    The Independent Order of Foresters - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Zai Lab Ltd (ZLAB):製薬・医療:M&Aディール及び事業提携情報
    Summary Zai Lab Ltd (Zai Lab) is a biopharmaceutical company that discovers, develops and manufactures transformative medicines for cancer, autoimmune and infectious diseases. The company’s pipeline products include ZL-2306, ZL-2401, FPA144, EXT2514SUL, ZL-2301, ZL-3101, ZL-2302 and ZL-1101. It deve …
  • Capstone Therapeutics Corp (CAPS)-製薬・医療分野:企業M&A・提携分析
    Summary Capstone Therapeutics Corp (Capstone), formerly OrthoLogic Corp is a biotechnology company that develops novel peptides and other molecules. The company develops novel peptides to support patients with under-served medical conditions. It develops AZX100 and Chrysalin drug platforms. Capstone …
  • Expro Holdings UK 2 Limited:企業の戦略的SWOT分析
    Expro Holdings UK 2 Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Oneness Biotech Co Ltd (4743):企業の財務・戦略的SWOT分析
    Summary Oneness Biotech Co Ltd (Oneness Biotech) is a bio pharmaceutical company that conducts research and development of drugs. The company provides products such as anti acne products. Its technologies comprise GAP cultivation platform, medicinal material identification, and separation and purifi …
  • Sunsweet Growers Inc.:戦略・SWOT・企業財務分析
    Sunsweet Growers Inc. - Strategy, SWOT and Corporate Finance Report Summary Sunsweet Growers Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Collagen Solutions Plc (COS):医療機器:M&Aディール及び事業提携情報
    Summary Collagen Solutions Plc (Collagen Solutions), formerly Healthcare Investment Opportunities Plc, is a medical device company that develops, manufactures and supplies medical grade collagen biomaterials and components. The company provides sourcing and supply of high grade collagen; provision o …
  • DPT Laboratories Ltd:企業の戦略的SWOT分析
    DPT Laboratories Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Sime Darby Berhad (SIME)-エネルギー分野:企業M&A・提携分析
    Summary Sime Darby Berhad (Sime Darby) is a trading and logistics company. It operates as a conglomerate that provides diversified products and services through its subsidiaries, affiliates, and joint ventures. The company cultivates oil palm, rubber, sugar cane, and cattle rearing and produces oil …
  • Shanghai SECCO Petrochemical Co Ltd:企業の戦略的SWOT分析
    Shanghai SECCO Petrochemical Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Ferrellgas Partners, L.P.:企業の戦略・SWOT・財務分析
    Ferrellgas Partners, L.P. - Strategy, SWOT and Corporate Finance Report Summary Ferrellgas Partners, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • AltheaDx Inc-医療機器分野:企業M&A・提携分析
    Summary AltheaDx Inc (AltheaDx) is a biotechnology company that offers molecular diagnostic services. The company provides tests such as cardiovascular tests, pain tests, thrombophilia tests and psychiatric tests. It provides diagnostic development, clinical trial and discovery services. AltheaDx’ s …
  • Vitabiotics Ltd:企業の戦略的SWOT分析
    Vitabiotics Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Roche Diagnostics International Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Roche Diagnostics International Ltd (Roche Diagnostics) offers novel diagnostic tests and systems for the early identification, targeted screening, assessment and monitoring of diseases. Its major products include point-of-care testing devices; analyzers, blood glucose meters; laboratory inf …
  • Lithia Motors, Inc.:企業のM&A・事業提携・投資動向
    Lithia Motors, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Lithia Motors, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Moog Inc (MOG.A):企業の財務・戦略的SWOT分析
    Moog Inc (MOG.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Hovnanian Enterprises Inc:戦略・SWOT・企業財務分析
    Hovnanian Enterprises Inc - Strategy, SWOT and Corporate Finance Report Summary Hovnanian Enterprises Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆